Malignant pleural mesothelioma

American Journal of Health-System Pharmacy

Volumn 69, Issue 5, 2012, Pages 377-385

  Chen, Sheree E ^a   Pace, Makala B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracyclines; Antineoplastic agents; Asbestos; Carboplatin; Cisplatin; Combined therapy; Diagnosis; Gemcitabine; Mesothelioma; Pemetrexed; Radiation; Site of action; Surgery; Taxanes; Vinorelbine

Indexed keywords

ANTHRACYCLINE; ASBESTOS; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PEMETREXED; TAXANE DERIVATIVE; VINBLASTINE SULFATE;

ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMAGE ANALYSIS; LEUKOPENIA; MALIGNANT PLEURAL MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMATITIS; TREATMENT RESPONSE; VINCA; VOMITING;

EID: 84863262156     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110281     Document Type: Review

References (56)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353:1591-603. (Pubitemid 41434638)
2. National Cancer Institute. Mesothelioma age-adjusted SEER cancer incidence ratesa, 1980-2008, by race, sex and year of diagnosis. http://seer.cancer.gov/csr/1975-2008/results-merged/sect-17-mesothelioma.pdf (accessed 2011 Nov 17).
3. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data from 1973 through 2005. Crit Rev Toxicol. 2009; 39:576-88.
4. Hodgson JT, McElvenny DM, Darnton AJ et al. The expected burden of mesothelioma in Great Britain from 2005 to 2050. Br J Cancer. 2005; 9:587-93. (Pubitemid 40395543)
5. National Cancer Institute. SEER cancer statistics review, 1975-2008. http://seer.cancer.gov/csr/1975-2008/ (accessed 2011 Mar 30).
6. National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. The work-related lung disease surveillance report, 2002. www.cdc.gov/niosh/docs/2003-111/2003-111.html (accessed 2010 Dec 2).
7. Pass HI, Vogelzang NT, Hahn SM et al. Benign and malignant mesothelioma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott, Williams & Wilkins; 2008:1835-62.
8. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002; 29:2-17. (Pubitemid 34163530)
9. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17:260-71.
10. O'Reilly KM, McLaughlin AM, Beckett WS et al. Asbestos-related lung disease. Am Fam Physician. 2007; 75:683-8.
11. Yates DH, Corrin B, Stidolph PN et al. Malignant mesothelioma in south east England: clinicopathological experiences of 272 cases. Thorax. 1997; 52:507-12. (Pubitemid 27298500)
12. Environmental Protection Agency. Asbestos ban and phase out. www.epa.gov/asbestos/pubs/ban.html (accessed 2011 Jul 26).
13. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005; 366:397-408. (Pubitemid 41073959)
14. Pepper C, Jasani B, Navabi H et al. Simian virus 40 large T antigen primer specific DNA amplification in human pleural mesothelioma tissue. Thorax. 1996; 51:1074-6. (Pubitemid 26402816)
15. Strickler HD, Goedert JJ, Fleming M et al. Simian virus 40 and pleural mesothelioma in humans. Cancer Epidemiol Biomarkers Prev. 1996; 5:473-5. (Pubitemid 26182663)
16. Manfredi JJ, Dong J, Liu WJ et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005; 76:2602-9. (Pubitemid 40490058)
17. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009; 136:888-96.
18. Muscat JE, Wynder EL. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res. 1991; 52: 2263-7.
19. Ault JG, Cole RW, Jensen CG et al. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 1995; 55:792-8.
20. Kamp DW, Israbian VA, Preusen SE et al. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol. 1995; 268:471-80.
21. Adachi Y, Aoki C, Yoshio-Hoshino N et al. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer. 2006; 119:1303-11. (Pubitemid 44258804)
22. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193:468-75. (Pubitemid 32266815)
23. National Heart, Lung and Blood Institute. Diseases and conditions index: asbestos-related lung diseases. www.nhlbi.nih.gov/health/dci/Diseases/asb/asb- all.html (accessed 2010 Dec 2).
24. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996; 14:1-12.
25. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16:145-52. (Pubitemid 28041592)
26. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113:723-31. (Pubitemid 28130949)
27. Tammilehto L, Kivisaari L, Salminen US et al. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients. Lung Cancer. 1995; 12:25-34.
28. Higashihara M, Sunaga S, Tange T et al. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer. 1992; 70:2105-8.
29. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortications in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008; 135:620-6.
30. Trousse DS, Avaro JP, D'Journo XB et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009; 36:759-63.
31. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009; 1:36-41.
32. Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemothoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122:788-95.
33. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002; 38:111-21. (Pubitemid 35157753)
34. Alimta (pemetrexed) package insert. Indianapolis, IN: Eli Lilly and Co.; 2010 Aug.
35. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
36. Kelland L. The resurgence of platinum based cancer chemotherapy. Nat Rev Cancer. 2007; 7:573-84. (Pubitemid 47106628)
37. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 11:1748-56. (Pubitemid 19272848)
38. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21:2636-44. (Pubitemid 46606305)
39. Ceresoli GL, Zucali PA, Favaretto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006; 24:1443-8. (Pubitemid 46622011)
40. Castagneto B, Botta M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008; 19:370-3.
41. Santoro A, O'Brien ME, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008; 3:756-63.
42. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999; 17:25-30. (Pubitemid 29022374)
43. Van Haarst JM, Baas P, Manegold C et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86:342-5. (Pubitemid 34187648)
44. Favaretto AG, Aversa SM, Paccagnella A et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003; 97:2791-7. (Pubitemid 36605147)
45. Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003; 21:1556-61. (Pubitemid 46594110)
46. Taylor P, Castagneto B, Dark G et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program. J Thorac Oncol. 2008; 3:764-71.
47. Muers MF, Stephens RJ, Fisher P et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008; 371:1685-94. (Pubitemid 351671885)
48. Steele JP, Shamash J, Evans MT et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18:3912-7.
49. Ellis P, Davies AM, Evans WK et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006; 1:591-601. (Pubitemid 47181411)
50. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26:1698-704.
51. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63:94-7.
52. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007; 25:2406-13. (Pubitemid 46999211)
53. Govindan R, Kratzke RA, Herndon JE II et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005; 11:2300-4. (Pubitemid 40490190)
54. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004; 22:3451-7. (Pubitemid 41103650)
55. Krug LM, Pass HI, Rusch VW et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Clin Oncol. 2009; 27:3007-13.
56. Karrison T, Kindler HL, Gandara DR et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma. J Clin Oncol. 2007 ASCO annual meeting proceedings, part I; 25(suppl):7526.